Advertisement

Growth Factors in Endometrial Cancer

  • Naoki Terakawa
Conference paper

Abstract

Progressive tumor growth has been associated with neovascularization induced by an angiogenic factor(s) that the tumor secretes (1). Therefore, inhibition of neovascularization could be effective in suppressing tumor growth (2). The antiproliferative effects of progestins in human endometrial cancer cells have been demonstrated by several investigators. Previously, we reported that the growth of human endometrial adenocarcinoma cells in primary culture was significantly suppressed by medroxyprogesterone acetate (MPA) (3); a similar growth-inhibitory effect has been reported in a nude mouse system (4). We have suggested that the antiproliferative effect of progestin on adenocarcinoma cells is mediated through progestin receptors (PR) present in the cells (5). In contrast, using the rabbit cornea assay, Gross et al. have shown that MPA inhibits the angiogenesis induced by several tumors of laboratory animals (6). Recent studies have shown that human endometrial adenocarcinoma cells produce angiogenic factors (7). Although MPA seems to act directly on endometrial cancer cells to inhibit their growth, the present data suggest that its inhibition of angiogenesis may share the same mechanism by which it inhibits the growth of endometrial adenocarcinoma. In the present study, to gain further information on MPA’s mechanism of action in human endometrial cancer, we examined MPA’s effect on angiogenesis induced by adenocarcinoma. We also investigated the synthesis and secretion of angiogenic growth factor(s) in a human endometrial cancer cell line.

Keywords

Endometrial Cancer Angiogenic Factor Medroxyprogesterone Acetate Endometrial Cancer Cell Endometrial Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447.PubMedCrossRefGoogle Scholar
  2. 2.
    Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Terakawa N, Ikegami H, Shimizu I et al (1988) Inhibitory effects of danazol and medroxyprogesterone acetate on [3H]thymidine incorporation in human endometrial cancer cells. J Steroid Biochem 31:131–135.PubMedCrossRefGoogle Scholar
  4. 4.
    Zaino RJ, Satyaswaroop PG, Mortel R (1985) Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Res 45:539–541.Google Scholar
  5. 5.
    Terakawa N, Hayashida M, Shimizu I (1987) Growth inhibition by progestins in a human endometrial cancer cell line with estrogen- independent progesterone receptors. Cancer Res 47:1918–1923.PubMedGoogle Scholar
  6. 6.
    Gross J, Azizkhan RG, Biswas C (1981) Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. Proc Natl Acad Sci USA 78:1176–1180.PubMedCrossRefGoogle Scholar
  7. 7.
    Ishiwata I, Ishiwata C, Soma M (1988) Tumor angiogenic activity of gynecologic tumor cell lines on chorioallantoic membrane. Gynecol Oncol 29:87–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Jikihara H, Terada N, Yamamoto R (1992) Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. Am J Obstet Gynecol 167:207–211.PubMedGoogle Scholar
  9. 9.
    Kauppila AJI, Isotalo HE, Kivinen ST, Vihko RK (1986) Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 46:5380–5384.PubMedGoogle Scholar
  10. 10.
    Gronroos M, Maenpaa J, Kangas R (1987) Steroid receptors and response of endometrial cancer to hormones in vitro. Ann Chir Gynecol 76:76–79.Google Scholar
  11. 11.
    Presta M, Maier JAM, Rusnati (1988) Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor-β. Cancer Res 48:6384–6389.PubMedGoogle Scholar
  12. 12.
    Fujimoto J, Fujita H, Hosoda S (1989) Effect of medroxy-progesterone acetate on secondary spreading of endometrial cancer. Invasion Metastasis 9:209–215.PubMedGoogle Scholar
  13. 13.
    Gong Y, Anzai Y, Murphy LC (1991) Transforming growth factor gene expression in human endometrial adenocarcinoma cells: Regulation by progestins. Cancer Res 51:5476–5481.PubMedGoogle Scholar
  14. 14.
    Ashino-Fuse H, Takano Y, Oikawa T (1989) Medroxy-progesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer 44:859–864.PubMedCrossRefGoogle Scholar
  15. 15.
    Derynck R, Jarrett JA, Chen EY (1985) Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 316:701–705.PubMedCrossRefGoogle Scholar
  16. 16.
    Kondaiah P, Sands MJ, Smith JM (1990) Identification of a novel transforming growth factor-β (TGF-P5) mRNA in Xenopus laevis. J Biol Chem 265:1089–1093.PubMedGoogle Scholar
  17. 17.
    Murray K, Haussler CA, Trookman NS (1987) Divergent effects of epidermal growth factor and transforming growth factors on a human endometrial carcinoma cell line. Cancer Res 47:4909–4914.Google Scholar
  18. 18.
    Knabbe C, Lippman ME, Wakefield LM (1987) Evidence that transforming growth factor p is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417–428.PubMedCrossRefGoogle Scholar
  19. 19.
    Boyd JA, Kaufman DG (1990) Expression of transforming growth factor p, by human endometrial carcinoma cell lines: Inverse correlation with effects on growth rate and morphology. Cancer Res 50:3394–3399.PubMedGoogle Scholar
  20. 20.
    Croxtall JD, Jamil A, Ayub M (1992) TGF-β stimulation of endometrial and breast-cancer cell growth. Int J Cancer 50:822–827.PubMedCrossRefGoogle Scholar
  21. 21.
    Jikihara H, Ikegami H, Sakata M (1991) Epidermal growth factor attenuates cell proliferation by down-regulating transforming growth factor-β receptor in the osteoblastic cell line MC3T3-E1. Bone Mineral 15:125–136.CrossRefGoogle Scholar
  22. Sakata N, Kurachi H, Ikegami H (1993) Autocrine growth mechanism by transforming growth factor (TGF)β1 and TGF-β1 receptor regulation by epidermal growth factor in a human endometrial cancer cell line IK-90. Int J Cancer 54:862–867.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1996

Authors and Affiliations

  • Naoki Terakawa

There are no affiliations available

Personalised recommendations